One Wales Medicines interim decisions

Rituximab for pemphigus and pemphigoid (OW10)

Last review date: July 2023

Sorafenib for acute myeloid leukaemia (AML) maintenance (OW18)

Last review date: June 2023

Trametinib (Mekinist®) for recurrent low grade serous ovarian carcinoma (OW30)

Last review date: September 2026

Ustekinumab for the treatment of inflammatory bowel disease in children (OW25)

Last review date: September 2026

Vedolizumab (Entyvio®) for the treatment of ICI induced enterocolitis (OW22)

Last review date: March 2026

Vedolizumab (Entyvio®) for the treatment of inflammatory bowel disease in children (OW24)

Last review date: May 2024

Venetoclax with azacitidine for relapsed/refractory acute myeloid leukaemia (OW32)

Issue date: December 2025

Vonicog alfa (Veyvondi®) for on-demand treatment of bleeding episodes in children with von Willebrand Disease (OW19)

Last review date: December 2024